Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRGF for Diabetic Foot Ulcers
2023-504275-24-01Phase 4Authorised
- Sponsor
- BTI Biotechnology Institute
- Start
- May 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 4, randomised trial of PRGF-Endoret in diabetic foot ulcer (DFU), diabetes mellitus type 1 (T1D), type 2 diabetes mellitus (T2DM) and 1 more (2 arms), sponsored by BTI Biotechnology Institute. Planned start May 2024; status: authorised.
02
Drugs
PRGF-Endoret
03
Conditions
diabetic foot ulcer (DFU)diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)arteriosclerosis obliterans
Beyond the preview
Go deeper on 2023-504275-24-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504275-24-01.